Skip to main content
Signal8
Launch Terminal

Iambic Therapeutics, Inc. (IAM)

Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Iambic Therapeutics Inc. logo

Iambic Therapeutics Inc.

NASDAQ:IAMTechnology
-2.79%$14.26
AH Close$14.34+0.56%vs close
Mkt Cap$675.94M
Float34.5M
O/S47.4M
Inst Own-
Dilution
Iambic Therapeutics Inc. logoNASDAQ:IAM$14.26-2.79%
FormDescription
4
PRIMARY DOCUMENT
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
8-K
5.03,7.01,9.01
2
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
424B4
Prospectus
7
S-8
SEC Filing
1
EFFECT
Notice of Effectiveness
3
PRIMARY DOCUMENT
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership

1-25 of 46